RxDoctor Payments Data

Celso Agner

Vascular Neurology · Fort Lauderdale, FLNPI 1194728964

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.2% of the total across 58 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Penumbra, Inc. at 35.1% of the total. 2025 is the largest year on record at $408, 6.6 times the $62 reported in 2019. That places this record below the midpoint for vascular neurology clinicians in FL, where the typical reported total is $1,787.

$1,676in general payments, 2019–2025

Across 58 payments — averaging $28.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$588
  • AstraZeneca$250
  • Medtronic$206
  • Microvention, Inc.$190
  • Boston Scientific$180
  • Qapel Medical Inc$52
  • plus $210 from 7 others

What the payments were for

  • Food & beverage$1,66299%
  • Education$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,676 in reported general payments places this provider in the 45th percentile of 40 vascular neurology providers in Florida.

See all vascular neurology providers in Florida

Medicare billing

Part B allowed, 2024
$107,279
Medicare patients
210
Services billed
787

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxcarbazepine14$2,165
Rivastigmine11$2,049
Lacosamide20$1,839
Levetiracetam53$926
Pregabalin33$618
Lamotrigine19$576
Carbidopa-LevodopaCarbidopa/Levodopa43$537
ClopidogrelClopidogrel Bisulfate50$532
Modafinil12$405
Duloxetine Hcl17$312
Atorvastatin Calcium27$227
Quetiapine Fumarate12$204
Gabapentin18$195
Diazepam14$131
Ropinirole Hcl13$124

Paid to pharmacies, not to this prescriber.

Other vascular neurology in Fort Lauderdale

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →